In noncardioembolic ischemic stroke or high-risk TIA, asundexian reduced ischemic stroke and did not increase major bleeding

“Asundexian holds the potential to reduce the risk of a recurrent stroke over the long term without an increased safety risk. This is a major advance in our ability to prevent strokes in people at risk of stroke recurrence.”

“The trial is very groundbreaking for us clinicians who take care of stroke patients because it expands our armamentarium of secondary stroke prevention tools that we can offer our patients as an adjunctive therapy without incurring the competing risk of hemorrhage. The ability to reduce recurrent strokes is so meaningful, because then we ensure that our patients are living longer, disability-free lives after their initial stroke.”

“The benefit of the Factor XIa inhibitors is that they're relatively selective; they act against the bad clot without harming the good clotting that's part of healing. But that was not the case with asundexian in this study. Essentially, patients benefited from a reduction in their ischemic stroke risk without a concomitant increase in bleeding risk. And this is critically important.”